Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.005 per share
-
Shares outstanding
-
7,939,798
-
Total 13F shares
-
49,811
-
Share change
-
+49,801
-
Total reported value
-
$91,652
-
Price per share
-
$1.84
-
Number of holders
-
12
-
Value change
-
+$91,634
-
Number of buys
-
11
Institutional Holders of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) as of Q2 2025
As of 30 Jun 2025,
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,811 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, Corient Private Wealth LLC, Sippican Capital Advisors, BlackRock, Inc., MORGAN STANLEY, UBS Group AG, ASSETMARK, INC, EverSource Wealth Advisors, LLC, BANK OF AMERICA CORP /DE/, and BNP PARIBAS FINANCIAL MARKETS.
This page lists
12
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.